Telmidiqual^®

Ingredient

Telmisartan/ Amlodipine

Content

40/5mg 40/10mg 80/5mg

Indication

Treatment of essential hypertension.

Telmidiqual is indicated in adult patients whose blood pressure is not adequately controlled on Telmisartan or Amlodipine monotherapy

Tenelia M SR Tab. 10/500mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 500mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

Tenelia M SR Tab. 10/750mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 15.5mg (10mg as Teneligliptin), Metformin Hydrochloride 750mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

Tenelia M SR Tab. 20/1000mg

Ingredient

Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride

Content

Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin), Metformin Hydrochloride 1000mg

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes who are adequate to combination therapy of teneligliptin and metformin.

Tenelia Tab. 20mg

Ingredient

Teneligliptin Hydrobromide Hydrate

Content

Teneligliptin Hydrobromide Hydrate 31mg (20mg as Teneligliptin)

Indication

This drug is administered as an adjunct to diet and exercise to improve the glucose control of patients with type 2 diabetes.
– Monotherapy
– Combination therapy

Toviaz SR Tab.

Ingredient

Fesoterodine fumarate

Content

Toviaz SR Tab. 4mg: Fesoterodine fumarate 4mg
Toviaz SR Tab. 8mg: Fesoterodine fumarate 8mg

Indication

Overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency

Trental SR Tab. 400

Ingredient

Pentoxifylline

Content

400mg

Indication

1) Improvement of cerebral circulation disorder (ischemia or post stroke symptoms and symptoms of cerebral arteriosclerosis like dizziness, headache, amnesia, and so on)
2) Improvement of eye circulation disorder
3) Improvement of peripheral arterial circulation disorder (Intermittent claudication, pain at rest, diabetic angiopathy, kraurosis, and vascular neuropathy)

Triapin Tab.

Ingredient

Felodipine/Ramipril

Content

2.5mg/2.5mg, 5mg/5mg

Indication

Treatment of essential hypertension.

Tritace Protect Tab.

Ingredient

Hydroxypropylmethylcellulose-coated Ramipril Granule

Content

11.765mg (10mg as Ramipril)

Indication

1) Treatment of hypertension
2) Treatment of heart failure post myocardial infarction
3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
– Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)

Tritace Tab.

Ingredient

Ramipril

Content

2.5mg, 5mg

Indication

1) Treatment of hypertension.
2) Treatment of heart failure post myocardial infarction
3) Reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in patients over 55 years of age with clinical evidence of cardiovascular disease (myocardial infarction, unstable angina, past history of polyvascular coronary bypass graft or polyvascular percutaneous coronary angioplasty), stroke or peripheral vascular disease. Also reduction in risk of death or the need for revascularization from myocardial infarction, stroke, cardiovascular disease in diabetic patients over 55 years of age who have one or more of the following clinical symptoms: Hypertension (systolic blood pressure exceeds 160mmHg or diastolic blood pressure exceeds 90 mmHg), high total cholesterol level (above 5.2 mmol/L), low high-density lipoprotein level (less than 0.9 mmol/L), smoker, history of microalbuminuria or past vascular disease
4) Treatment of the following clinical symptoms in diabetic patients: Early nephropathy with microalbuminuria (30­300mg/24h), overt glomerular nephropathy, proteinuria (>500mg/24h)
– Treatment of non-diabetic overt glomerular nephropathy (when creatinine clearance is 20-70 mL/min) or proteinuria (≥3g/24h)